349 related articles for article (PubMed ID: 32629125)
41. Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion.
Yang C; Guo G; Li B; Zheng L; Sun R; Wang X; Deng J; Jia G; Zhou X; Cui L; Guo C; Zhou X; Leung PSC; Gershwin ME; Shang Y; Han Y
Hepatol Int; 2023 Feb; 17(1):237-248. PubMed ID: 36309918
[TBL] [Abstract][Full Text] [Related]
42. Proposed therapies in primary biliary cholangitis.
Floreani A; Sun Y; Zou ZS; Li B; Cazzagon N; Bowlus CL; Gershwin ME
Expert Rev Gastroenterol Hepatol; 2016; 10(3):371-382. PubMed ID: 26577047
[TBL] [Abstract][Full Text] [Related]
43. Efficacy of ursodeoxycholic acid for primary biliary cholangitis: Experience from a tertiary care centre in Saudi Arabia.
AlWabel AH; Peedikayil M; AlNasser S; AlHusaini K; AlHekail O; Alqahtani SA; AlTraif IH; AlAshgar H
Saudi J Gastroenterol; 2023; 29(2):135-140. PubMed ID: 35229756
[TBL] [Abstract][Full Text] [Related]
44. Management of primary biliary cholangitis prior to obeticholic acid availability.
Durazzo M; Bonetto S; Fagoonee S; Morgando A; Pellicano R
Minerva Med; 2018 Dec; 109(6):410-417. PubMed ID: 30022645
[TBL] [Abstract][Full Text] [Related]
45. A validation study of the Ursodeoxycholic Acid Response Score in Japanese patients with primary biliary cholangitis.
Yagi M; Matsumoto K; Komori A; Abe M; Hashimoto N; Inao M; Namisaki T; Kawata K; Ninomiya M; Fujii H; Takahashi A; Kang JH; Takamura M; Arakawa M; Joshita S; Sato K; Itakura J; Nomura T; Kakisaka K; Kaneko A; Tamura Y; Miura R; Aiso M; Arizumi T; Asaoka Y; Kikuchi K; Takikawa Y; Masaki T; Umemura T; Honda A; Ohira H; Kawada N; Yoshiji H; Mochida S; Takikawa H; Tanaka A;
Liver Int; 2020 Aug; 40(8):1926-1933. PubMed ID: 32438508
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and Safety of Bezafibrate Alone or in Combination with Ursodeoxycholic Acid in Primary Biliary Cholangitis: Systematic Review and Meta-Analysis.
Khakoo NS; Sultan S; Reynolds JM; Levy C
Dig Dis Sci; 2023 Apr; 68(4):1559-1573. PubMed ID: 36180756
[TBL] [Abstract][Full Text] [Related]
47. Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis.
Efe C; Taşçilar K; Henriksson I; Lytvyak E; Alalkim F; Trivedi H; Eren F; Eliasson J; Beretta-Piccoli BT; Fischer J; Calişkan AR; Chayanupatkul M; Coppo C; Ytting H; Purnak T; Muratori L; Werner M; Muratori P; Rorsman F; Önnerhag K; Günşar F; Nilsson E; Heurgué-Berlot A; Güzelbulut F; Demir N; Gönen C; Semela D; Aladağ M; Kiyici M; Schiano TD; Montano-Loza AJ; Berg T; Ozaslan E; Yoshida EM; Bonder A; Marschall HU; Wahlin S
Am J Gastroenterol; 2019 Jul; 114(7):1101-1108. PubMed ID: 31241547
[TBL] [Abstract][Full Text] [Related]
48. Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy.
Babatin MA; Sanai FM; Swain MG
Aliment Pharmacol Ther; 2006 Sep; 24(5):813-20. PubMed ID: 16918885
[TBL] [Abstract][Full Text] [Related]
49. Response to Ursodeoxycholic Acid May Be Assessed Earlier to Allow Second-Line Therapy in Patients with Unresponsive Primary Biliary Cholangitis.
Cançado GGL; Couto CA; Terrabuio DRB; Cançado ELR; Villela-Nogueira CA; Ferraz MLG; Braga MH; Nardelli MJ; Faria LC; de Faria Gomes NM; Oliveira EMG; Rotman V; Oliveira MB; da Cunha SMCF; Cunha-Silva M; Mendes LSC; Ivantes CAP; Codes L; de Almeida E Borges VF; de Lima Pace FH; Pessoa MG; Guedes LV; Signorelli IV; Coral GP; Levy C; Bittencourt PL;
Dig Dis Sci; 2023 Feb; 68(2):514-520. PubMed ID: 35989386
[TBL] [Abstract][Full Text] [Related]
50. Bezafibrate therapy in primary biliary cholangitis refractory to ursodeoxycholic acid: a longitudinal study of paired liver biopsies at 5 years of follow up.
Sorda JA; González Ballerga E; Barreyro FJ; Avagnina A; Carballo P; Paes de Lima A; Daruich J
Aliment Pharmacol Ther; 2021 Nov; 54(9):1202-1212. PubMed ID: 34587309
[TBL] [Abstract][Full Text] [Related]
51. Dynamic Risk Prediction of Response to Ursodeoxycholic Acid Among Patients with Primary Biliary Cholangitis in the USA.
Li J; Lu M; Zhou Y; Bowlus CL; Lindor K; Rodriguez-Watson C; Romanelli RJ; Haller IV; Anderson H; VanWormer JJ; Boscarino JA; Schmidt MA; Daida YG; Sahota A; Vincent J; Wu KH; Trudeau S; Rupp LB; Melkonian C; Gordon SC;
Dig Dis Sci; 2022 Aug; 67(8):4170-4180. PubMed ID: 34499271
[TBL] [Abstract][Full Text] [Related]
52. Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. Dutch Multi-Centre PBC Study Group.
van Hoogstraten HJ; Hansen BE; van Buuren HR; ten Kate FJ; van Berge-Henegouwen GP; Schalm SW
J Hepatol; 1999 Aug; 31(2):256-62. PubMed ID: 10453938
[TBL] [Abstract][Full Text] [Related]
53. Worse Response to Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients with Autoimmune Hepatitis Features.
Wen M; Men R; Fan X; Shen Y; Ni P; Hu Z; Yang L
Dig Dis; 2021; 39(4):366-374. PubMed ID: 33238269
[TBL] [Abstract][Full Text] [Related]
54. Disease-modifying therapies and symptomatic management for primary biliary cholangitis.
Patel R; Portone G; Lambert JA; Mak S; Alrubaiy L
Br J Hosp Med (Lond); 2021 Nov; 82(11):1-9. PubMed ID: 34817254
[TBL] [Abstract][Full Text] [Related]
55. Treatment of Primary Biliary Cholangitis including Transplantation.
Muzahim Y; Wakil A; Bassi M; Pyrsopoulos N
Clin Liver Dis; 2024 Feb; 28(1):103-114. PubMed ID: 37945152
[TBL] [Abstract][Full Text] [Related]
56. Excellent outcome in patients with primary biliary cholangitis in Northwest Italy followed up for up to 30 years.
Rigamonti C; De Benedittis C; Labanca S; Vanni E; Morgando A; Manfredi GF; Azzolina D; Cittone MG; Giannini EG; Saracco GM; Pirisi M
Eur J Gastroenterol Hepatol; 2023 Aug; 35(8):899-906. PubMed ID: 37395243
[TBL] [Abstract][Full Text] [Related]
57. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid.
Hazzan R; Tur-Kaspa R
J Clin Gastroenterol; 2010; 44(5):371-3. PubMed ID: 19881358
[TBL] [Abstract][Full Text] [Related]
58. How the concept of biochemical response influenced the management of primary biliary cholangitis over time.
Lammers WJ; Leeman M; Ponsioen CI; Boonstra K; van Erpecum KJ; Wolfhagen FH; Kuyvenhoven JP; Vrolijk JM; Drenth JP; Witteman EM; van Nieuwkerk CM; van der Spek BW; Witteman BJ; Erkelens GW; Verhagen MA; van Tuyl SA; Poen AC; Brouwer JT; Ter Borg F; Koek GH; van Ditzhuijsen TJ; Hansen BE;
Neth J Med; 2016 Jul; 74(6):240-6. PubMed ID: 27571721
[TBL] [Abstract][Full Text] [Related]
59. Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one-year non-responders and predicts survival.
Murillo Perez CF; Ioannou S; Hassanally I; Trivedi PJ; Corpechot C; van der Meer AJ; Lammers WJ; Battezzati PM; Lindor KD; Nevens F; Kowdley KV; Bruns T; Cazzagon N; Floreani A; Mason AL; Gulamhusein A; Ponsioen CY; Carbone M; Lleo A; Mayo MJ; Dalekos GN; Gatselis NK; Thorburn D; Verhelst X; Parés A; Londoño MC; Janssen HLA; Invernizzi P; Vuppalanchi R; Hirschfield GM; Hansen BE; Levy C;
Liver Int; 2023 Jul; 43(7):1497-1506. PubMed ID: 37157905
[TBL] [Abstract][Full Text] [Related]
60. Biochemical response to ursodeoxycholic acid predicts survival in a North American cohort of primary biliary cirrhosis patients.
Lammert C; Juran BD; Schlicht E; Chan LL; Atkinson EJ; de Andrade M; Lazaridis KN
J Gastroenterol; 2014 Oct; 49(10):1414-20. PubMed ID: 24317935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
